Brooks Laboratories Limited (BROOKS)
₹67.57 -4.05% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Brooks Laboratories' revenue was ₹23.0 Cr (-10.0% year on year, +13.6% on the previous quarter), and net profit ₹-1.8 Cr (against a profit a year earlier); the operating margin was 8.1%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹23.0 | -10.0% | +13.6% |
| Operating profit | ₹1.9 | -40.4% | +173.9% |
| Net profit | ₹-1.8 | to loss | to loss |
| EPS (₹) | -0.61 | to loss | to loss |
| Operating margin | 8.1% | — | — |
BROOKS delivery percentage and bulk deals
NSE end-of-day data for
On Fri, 16 Oct 2026, 55.23% of the BROOKS shares traded on NSE were taken to delivery, against the stock's own 20-session average of 60.93%. That is close to its usual level. Turnover was only ₹84 lakh, so a handful of trades can move this figure. It closed at a price band (circuit) on 2 sessions in about the last 20. 2 bulk or block deals were reported in BROOKS in the last 60 days: ₹2 Cr bought and ₹2 Cr sold.
Delivery in the last 5 sessions: 52.2% · 40.0% · 46.4% · 43.8% · 55.2%
| Date | Side | Counterparty | Value | Price | Quantity | Type |
|---|---|---|---|---|---|---|
| 8 Oct | Sell | Amit Kumar Jain | ₹1.95 Cr | ₹70.24 | 278,062 | Bulk |
| 8 Oct | Buy | Amit Kumar Jain | ₹1.81 Cr | ₹70.26 | 258,042 | Bulk |
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Brooks Laboratories has approved a Scheme of Arrangement to demerge its Baddi manufacturing business into its wholly-owned subsidiary, Abridge Speciality Limited. The demerged undertaking accounted for Rs 82.87 crore (96.66%) of the company's FY26 total turnover. Under the scheme, shareholders will receive 1 share of Abridge Speciality for every 1 share held in Brooks Laboratories, with listing intended for the resulting entity on BSE and NSE. The residual business will focus on trading and be renamed Xuri Lifesciences, while Abridge Speciality will adopt the Brooks Laboratories name.
- Demerged business accounted for Rs 82.87 crore or 96.66% of FY26 total turnover
- Share entitlement ratio approved at 1:1 (one share of Abridge Speciality for each share of Brooks Labs)
- Abridge Speciality will issue 2,94,57,248 equity shares and seek listing on BSE and NSE
- Estimated timeline to final listing is approximately 16 months across 4 stages
- Expected capital availability of ~Rs 50 crore planned for strategic growth in each platform
Brooks Laboratories has approved a Scheme of Arrangement to demerge its Baddi manufacturing business into its wholly-owned subsidiary, Abridge Speciality Limited. The demerged undertaking accounted for Rs 82.87 crore (96.66%) of the company's FY26 total turnover. Under the scheme, shareholders will receive 1 share of Abridge Speciality for every 1 share held in Brooks Laboratories, with listing intended for the resulting entity on BSE and NSE. The residual business will focus on trading and be renamed Xuri Lifesciences, while Abridge Speciality will adopt the Brooks Laboratories name.
- Demerged business accounted for Rs 82.87 crore or 96.66% of FY26 total turnover
- Share entitlement ratio approved at 1:1 (one share of Abridge Speciality for each share of Brooks Labs)
- Abridge Speciality will issue 2,94,57,248 equity shares and seek listing on BSE and NSE
- Estimated timeline to final listing is approximately 16 months across 4 stages
- Expected capital availability of ~Rs 50 crore planned for strategic growth in each platform
Brooks Laboratories Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026. The certificate from Registrar and Share Transfer Agent MUFG Intime India Private Limited confirms compliance with depository processes. Notably, the RTA stated that no requests for dematerialisation or rematerialisation were received during the period. This is a standard quarterly administrative filing.
- Regulation 74(5) compliance confirmed for the quarter ended 30th September 2026
- Certificate issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited on 6th October 2026
- Zero dematerialisation or rematerialisation requests were received during the quarter
Brooks Laboratories has announced the resignation of Ms. Krutika Rane from the post of Company Secretary and Compliance Officer (Key Managerial Personnel). She tendered her resignation on September 16, 2026, to pursue an alternate career opportunity outside the organization. She will be relieved from her duties with effect from the close of business hours on October 9, 2026. The company is an Indian pharma formulation manufacturer with a market cap of approximately ₹180 Cr and TTM revenue of ₹83 Cr.
- Krutika Rane submitted resignation as Company Secretary and Compliance Officer on September 16, 2026
- Relieving date set for close of business hours on October 9, 2026
- Reason cited is to pursue an alternate career opportunity outside the organization
- Appointment of a successor was not disclosed in the filing
Brooks Laboratories announced the resignation of its Company Secretary and Compliance Officer (Key Managerial Personnel), Ms. Krutika Rane, on September 16, 2026. She is stepping down to pursue an alternate career opportunity outside the organization and will be relieved effective October 9, 2026. This administrative change does not impact the operational or financial performance of the company, which generated Rs 83 Cr in TTM revenue.
- Resignation tendered on September 16, 2026
- Relieving date confirmed as close of business hours on October 9, 2026
- Reason cited as pursuing an alternate career opportunity outside the organization
- Covers the statutory role of Company Secretary and Compliance Officer
Brooks Laboratories Limited announced the voting results and Scrutinizer's report for its 24th Annual General Meeting held on September 03, 2026. All 6 ordinary resolutions were passed with over 99.9% majority votes in favour. Approved agendas included adoption of audited financial statements, director reappointment, cost auditor remuneration, related party transactions, and remuneration approvals for two key management personnel.
- All 6 ordinary resolutions passed with >99.99% of polled votes in favour.
- Total shareholder count stood at 11,491 as of the record date (August 27, 2026).
- Approval granted for remuneration to Mr. Atul Ranchal (President - Strategy) and Mr. Rajesh Mahajan (President - Trading) under Section 188(1)(f).
- Meeting conducted via video conferencing with 8 promoter group members and 319 public shareholders attending.
Brooks Laboratories Limited conducted its 24th Annual General Meeting on September 3, 2026, via video conferencing with 319 members in attendance. Shareholders considered 7 ordinary resolutions, including the adoption of FY26 audited standalone and consolidated financial statements, re-appointment of retiring director Mr. Jitendrapratap Singh, and ratification of cost auditor remuneration. Additionally, resolutions regarding related-party transactions and remuneration approvals for executive roles under Section 188(1)(f) were tabled. Formal voting results and the scrutinizer's report will be declared separately within two working days.
- 24th AGM held on September 3, 2026, with 319 members present via VC/OAVM
- 7 ordinary resolutions tabled covering FY26 financial statements, director re-appointment, and auditor remuneration
- Resolutions placed for approval of related party transactions and remuneration to senior management personnel under Section 188(1)(f)
- Scrutinizer's final e-voting report to be submitted to exchanges within two working days
Brooks Laboratories Limited has issued an addendum to the notice for its 24th Annual General Meeting scheduled for September 3, 2026. The update modifies Resolution No. 4 and its explanatory statement to include shareholder approval and ratification for certain corporate guarantee arrangements under related party transactions. The original AGM notice dated July 31, 2026 was dispatched on August 12, 2026. All other resolutions and items in the FY26 Annual Report remain unchanged.
- 24th AGM scheduled for September 3, 2026 at 9:00 AM IST via Video Conferencing.
- Addendum updates Resolution No. 4 to cover corporate guarantee arrangement(s) with related parties.
- Original AGM notice was dispatched to shareholders on August 12, 2026.
- All other contents of the 24th AGM notice and FY26 annual report remain unchanged.
Brooks Laboratories Limited has notified the exchanges regarding its 24th Annual General Meeting (AGM) scheduled for September 3, 2026. The book closure period for the AGM will be from August 27, 2026, to September 3, 2026 (both days inclusive). The cut-off date to determine e-voting eligibility is August 27, 2026, with the e-voting window active from August 31, 2026 (9:00 AM IST) to September 2, 2026 (5:00 PM IST). This is a routine procedural compliance filing.
- 24th Annual General Meeting scheduled to take place on September 3, 2026.
- Book closure period defined from August 27, 2026, to September 3, 2026 (inclusive).
- E-voting cut-off date fixed as August 27, 2026.
- E-voting period opens August 31, 2026 (9:00 AM IST) and ends September 2, 2026 (5:00 PM IST).
Brooks Laboratories reported a weak start to FY27, with consolidated revenue declining 10% YoY to ₹22.96 Cr. The company swung to a consolidated net loss of ₹1.79 Cr, a sharp reversal from the ₹9.58 Cr profit recorded in Q1 FY26. This downturn was primarily caused by a ₹3.21 Cr share of loss from its joint venture, Brooks Steriscience Limited, which reported a total loss of ₹6.54 Cr for the quarter. While standalone operations remained profitable at ₹1.42 Cr, this was still a 46% decline from the previous year's ₹2.65 Cr.
- Consolidated revenue fell 10% YoY to ₹22.96 Cr from ₹25.51 Cr in the year-ago period
- Swung to a consolidated net loss of ₹1.79 Cr compared to a profit of ₹9.58 Cr in Q1 FY26
- Share of loss from Joint Venture (Brooks Steriscience) stood at ₹3.21 Cr, impacting the bottom line
- Standalone net profit declined 46.4% YoY to ₹1.42 Cr from ₹2.65 Cr
- Manufacturing segment revenue, the core business, decreased to ₹22.78 Cr from ₹25.15 Cr YoY
Brooks Laboratories has announced its 24th Annual General Meeting (AGM) to be held on September 3, 2026, via video conferencing. The company is dispatching physical letters to shareholders who have not registered their email addresses, providing access to the FY 2025-26 Annual Report. This follows a fiscal year where the company reported a TTM revenue of Rs 86 Cr and a PAT of Rs 25 Cr, marking a recovery from a loss of Rs 12.4 Cr in FY25. The filing also serves as a regulatory reminder for shareholders to update KYC details to ensure electronic receipt of future payments.
- 24th Annual General Meeting scheduled for September 3, 2026, at 09:00 AM IST
- Cut-off date for dispatching shareholder communications was August 7, 2026
- FY 2025-26 Annual Report made available on the company website for shareholder review
- TTM Revenue of Rs 86 Cr reported against a market capitalization of Rs 184 Cr
- Company targeting a scale-up to reach a Total Operating Income of ~Rs 100 Cr in FY26
Brooks Laboratories has scheduled its 24th Annual General Meeting (AGM) for September 3, 2026. Key resolutions include approving monthly remuneration of Rs 15 lakh for Mr. Atul Ranchal and Rs 8 lakh for Mr. Rajesh Mahajan, totaling Rs 2.76 crore annually. This combined compensation represents approximately 11% of the company's TTM Net Profit of Rs 25 crore. Additionally, the company is seeking approval for Related Party Transactions that may exceed 10% of its consolidated annual turnover.
- 24th Annual General Meeting scheduled for September 3, 2026, via Video Conferencing.
- Proposed remuneration for Mr. Atul Ranchal (President - Strategy) at Rs 15 lakh per month effective Sept 1, 2026.
- Proposed remuneration for Mr. Rajesh Mahajan (President - Trading) at Rs 8 lakh per month effective July 17, 2026.
- Seeking shareholder approval for Related Party Transactions exceeding 10% of consolidated turnover (approx. >Rs 8.6 cr).
- Ratification of Cost Auditor remuneration at Rs 60,000 plus applicable taxes for FY27.
Brooks Laboratories has appointed Mr. Rajesh Mahajan as President - Trading and Senior Management Personnel effective July 17, 2026. Mr. Mahajan brings over 20 years of experience in pharmaceutical formulations and manufacturing operations to the role. This leadership addition comes as the company targets a Total Operating Income (TOI) of Rs 100 Cr for FY26, representing a ~20% growth over FY25 levels. While the company has recently prioritized manufacturing for margin improvement (OPM 8.2%), this appointment suggests a continued focus on its trading segment.
- Appointment of Mr. Rajesh Mahajan as President - Trading effective July 17, 2026
- Mr. Mahajan brings 20+ years of experience in pharmaceutical formulations and manufacturing
- Company targeting a scale-up to Rs 100 Cr TOI in FY26 from Rs 83 Cr
- TTM Revenue stands at Rs 86 Cr with a Net Worth of Rs 121 Cr as of latest filings
Brooks Laboratories has executed a binding MoU to sell a 16.33% stake in its joint venture, Brooks Steriscience Limited (BSL), reducing its holding from 49.00% to 32.67%. The transaction is expected to bring an immediate cash inflow of Rs 106.33 crores, which is substantial given the company's TTM revenue of Rs 86 crores. The agreement includes a value protection framework for the remaining 32.67% stake, valuing it at a minimum of USD 22.87 million. This liquidity event provides significant capital for the company's stated growth and business expansion plans.
- Stake in Brooks Steriscience Limited to be reduced from 49.00% to 32.67% following the transaction.
- Immediate cash inflow of approximately Rs 106.33 crores to be utilized for growth and expansion.
- Value protection floor for the retained 32.67% stake set at a minimum of USD 22.87 million based on a USD 70 million business valuation.
- Future capital requirements for the existing business to be met primarily through debt financing to prevent further dilution.
- MoU is binding for a period of two years and includes provisions for the release of corporate guarantees extended by Brooks Labs.
Brooks Laboratories has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the period ended June 30, 2026. The certificate, issued by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited, confirms that the company has adhered to the necessary procedures for share dematerialization. Notably, the registrar reported that zero requests for dematerialization or rematerialization were received during this quarter. This is a standard administrative filing with no impact on the company's financial performance or business operations.
- Compliance certificate issued for the quarter ended 30th June 2026
- Reported 0 requests for dematerialization or rematerialization during the period
- Confirmation provided by Registrar MUFG Intime India Private Limited
- Filing submitted to BSE and NSE on 9th July 2026
Financial Performance
Revenue Growth by Segment
The company operates in two segments: Manufacturing and Trading. For the half-year ended September 30, 2025, Manufacturing revenue reached INR 4,652.08 Lakhs, representing approximately 95% of total segment revenue, while Trading revenue contributed INR 244.18 Lakhs. Total Operating Income (TOI) grew from INR 79.48 Cr in FY24 to INR 83.04 Cr in FY25, a growth of 4.48% YoY.
Geographic Revenue Split
Not explicitly disclosed in percentage terms; however, operations are concentrated in India with the registered office and manufacturing works located in Baddi, Himachal Pradesh, and corporate offices in Mumbai, Maharashtra.
Profitability Margins
Profitability showed significant improvement with PAT margins rising from 1.90% in FY24 to 3.68% in FY25. For H1 FY26, the company's share of profit from its joint venture, Brooks Steriscience Limited, was INR 1,267.38 Lakhs, which significantly bolsters consolidated net profitability.
EBITDA Margin
The PBILDT margin improved by 117 basis points, increasing from 4.86% in FY24 to 6.03% in FY25. This improvement was driven by better operational efficiencies and stronger supplier negotiations which lowered purchase costs.
Capital Expenditure
The company strengthened its liquidity through a successful rights issue in 2023, increasing share capital from INR 2,624.67 Lakhs to INR 2,945.72 Lakhs. Specific planned CAPEX for FY26 is not disclosed, but the focus remains on scaling the manufacturing segment.
Credit Rating & Borrowing
The long-term bank facilities rating was upgraded to CARE BB; Stable from CARE BB-; Stable in November 2025. Short-term facilities are rated CARE A4. Total rated bank facilities amount to INR 12.00 Cr (INR 7.80 Cr long-term and INR 4.20 Cr short-term).
Operational Drivers
Raw Materials
Pharmaceutical ingredients and chemicals required for manufacturing formulations; specific chemical names are not disclosed, but they represent a significant portion of the manufacturing cost base.
Key Suppliers
Not specifically named; however, the company noted that 'stronger supplier negotiations' are expected to drive higher profit margins in FY26 by reducing procurement costs.
Capacity Expansion
Current manufacturing operations are based in Baddi, HP. While specific MTPA capacity is not disclosed, the company is targeting a scale-up to reach a TOI of ~INR 100.00 Cr in FY26, implying increased utilization or capacity debottlenecking.
Raw Material Costs
Raw material costs are a primary driver of the 6.03% PBILDT margin. Management's strategy to improve margins relies on reducing these costs through bulk procurement and better credit terms with vendors.
Manufacturing Efficiency
Efficiency is reflected in the improvement of PBILDT margins from 4.86% to 6.03%. The company is focusing on manufacturing over trading to capture higher value-added margins.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
The company aims to achieve a TOI of INR 100 Cr in FY26 (up from INR 83 Cr) by focusing on its manufacturing segment, optimizing supplier costs to improve margins, and benefiting from the licensing income and operational scale of its Joint Venture, Brooks Steriscience Limited.
Products & Services
Pharmaceutical formulations, medicines, and licensing of pharmaceutical products/intellectual property through its joint venture.
Brand Portfolio
Brooks Laboratories, Brooks Steriscience.
New Products/Services
Licensing income from the JV (INR 3,913.14 Lakhs in H1 FY26) indicates a shift toward high-margin intellectual property and specialized pharmaceutical products.
Market Expansion
The company is leveraging its JV to expand its reach, with the JV recording revenue of INR 6,782.45 Lakhs in just six months.
Market Share & Ranking
Not disclosed; company is characterized as having a 'small scale of operations' in a competitive industry.
Strategic Alliances
Joint Venture with Brooks Steriscience Limited, where Brooks Laboratories holds a significant stake and shares 50% of the profit after tax (INR 1,267.38 Lakhs share in H1 FY26).
External Factors
Industry Trends
The pharmaceutical industry is evolving toward higher compliance standards and specialized formulations. Brooks is positioning itself by shifting focus to manufacturing and leveraging JV licensing income, which grew to represent a major portion of JV revenue (INR 3,913.14 Lakhs).
Competitive Landscape
Operates in a fragmented and highly competitive market with numerous domestic and international pharmaceutical players.
Competitive Moat
The moat is based on the 'established track record of operations' and 'experienced promoters'. However, the moat is narrow given the small scale and high competition, making the JV's performance critical for sustainability.
Macro Economic Sensitivity
Sensitive to healthcare spending and pharmaceutical regulatory policies in India.
Consumer Behavior
Increased demand for quality pharmaceutical formulations and specialized medicines.
Geopolitical Risks
Potential trade barriers or regulatory changes affecting pharmaceutical exports or raw material imports from global suppliers.
Regulatory & Governance
Industry Regulations
Subject to stringent pharmaceutical manufacturing standards and periodic inspections. The company must comply with Ind AS 108 for segment reporting and other statutory requirements under the Companies Act 2013.
Taxation Policy Impact
The company has not recognized deferred tax assets on business losses/depreciation due to a lack of 'reasonable certainty of taxable profit', indicating a conservative but cautious tax position.
Legal Contingencies
The Auditor's Report (CARO 2024-25) noted qualifications/adverse remarks under Clause 3(ii)(b) and 3(vii)(b) for the holding company, and several clauses for the JV, indicating some areas of regulatory or internal control friction.
Risk Analysis
Key Uncertainties
The primary uncertainty is the 'absence of reasonable certainty of taxable profit', which prevents the recognition of deferred tax assets. Additionally, the reliance on the JV for a significant portion of consolidated profits (INR 12.67 Cr in H1 FY26) creates a dependency risk.
Geographic Concentration Risk
High concentration in Baddi, Himachal Pradesh for manufacturing operations.
Third Party Dependencies
High dependency on the performance of the Jointly Controlled Entity, Brooks Steriscience Limited, for consolidated bottom-line growth.
Technology Obsolescence Risk
The company is maintaining an 'audit trail' feature in its accounting software since April 2023 to comply with new regulations, showing a commitment to digital compliance.
Credit & Counterparty Risk
Trade payables stood at INR 1,362.43 Lakhs (Consolidated) as of March 31, 2025, reflecting ongoing working capital management requirements.
